Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms

Fanming Kong; Chaoran Wang; Linlin Zhao; Dongying Liao; Xiaoqun Wang; Binxu Sun; Peiying Yang; Yingjie Jia

doi:10.1016/j.chmed.2023.05.004

Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms

Chin Herb Med. 2023 Sep 21;15(4):509-515. doi: 10.1016/j.chmed.2023.05.004. eCollection 2023 Oct.

Authors

Fanming Kong^{1

2}, Chaoran Wang^{1

2

3}, Linlin Zhao^{1

2}, Dongying Liao^{1

2

3}, Xiaoqun Wang^{1

2}, Binxu Sun^{1

2}, Peiying Yang^{1

2}, Yingjie Jia^{1

2}

Affiliations

¹ Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
² National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
³ Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

Abstract

The most common subtype of lung cancer is non-small cell lung cancer (NSCLC), which has a poor prognosis and seriously threatens the health of human beings. The multidisciplinary comprehensive treatment model has gradually become the mainstream of NSCLC treatment. Traditional Chinese medicine (TCM) can be used effectively either as an adjunctive therapy or alone throughout the NSCLC therapy, which has a significant impact on survival, quality of life, and reduction of toxicity. Therefore, this paper reviewed the theoretical basis, the latest clinical application, and combined treatment mechanisms in order to explore the advantage stage of TCM treatment and the synergistic therapeutic mechanisms.

Keywords: advantage stage; clinical application; mechanisms; non-small cell lung cancer; synergistic therapeutic; theoretical basis; traditional Chinese medicines; treatment model.

Publication types

Review